Immunic Secures Key European Patent for Vidofludimus Calcium Dosing Regimens
In a substantial advancement for the biotechnology sector, Immunic, Inc. (Nasdaq: IMUX), a company specializing in novel oral treatments for neurologic and gastrointestinal diseases, has successfully secured a pivotal European patent. This patent, designated as EP3713554, is focused on the dosing regimens pertinent to their lead compound, vidofludimus calcium (IMU-838). The organization announced on March 10, 2026, that this protection is intended to maintain market exclusivity for vidofludimus calcium through 2038, with potential for extension until 2043 through a Supplementary Protection Certificate (SPC).
The patent not only covers the drug itself but extends to various forms, including salts and solvates, used in all dosing regimens as indicated on the label. This comprehensive coverage ensures that even alternative formulations would be protected under the patent, positioning Immunic advantageously within the marketplace. Daniel Vitt, Immunic's Chief Executive Officer, articulated the importance of this development, indicating that it significantly bolsters the company's competitive edge against other forms of treatment for diseases, including multiple sclerosis (MS).
What’s more, the recent patent aligns with Immunic's multipronged intellectual property strategy, which includes a robust portfolio of additional patents. These cover aspects such as the drug's composition of matter, treatment protocols for multiple sclerosis, and various dosing methodologies derived from clinical trials. With these patents set to protect their innovations until at least 2041 in the U.S. and 2039 in Europe, Immunic positions itself for long-term success in a rapidly evolving industry.
Vidofludimus calcium employs a unique mechanism that integrates neuroprotective, anti-inflammatory, and anti-viral properties targeting the intricate pathology of multiple sclerosis. By selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH), it has demonstrated the ability to activate the nuclear receptor-related 1 (Nurr1), a transcription factor linked to neuroprotection. Currently, vidofludimus is undergoing late-stage clinical trials for treating relapsing MS, with phase 2 results indicating promising efficacy in reducing brain lesions and alleviating disability progression. The positive outcomes observed in clinical settings underscore the drug's potential, with over 3,400 participants already exposed to the treatment, asserting its acceptable safety and tolerability profile.
In addition to ms, future applications for vidofludimus calcium might address other neurodegenerative diseases, based on ongoing patent applications. These seek to expand the application of the drug to other forms and indicates a strategic foresight by Immunic to leverage their IP portfolio effectively. As they continue to pursue regulatory approval, Immunic remains committed to reinforcing its market position, primarily through the development of vidofludimus calcium and its associated conditions.
Immunic's reach isn't confined to just the European market; their patent strategy is global, adhering to various jurisdictions and reinforcing their stance in a competitive landscape. As they continue to innovate and evolve their product line, Immunic is poised to make a significant impact in treating chronic inflammatory and autoimmune diseases worldwide.
In summary, the securing of this European patent is not merely a legal victory but a critical step in solidifying Immunic’s status as a leader in biotechnology, amplifying its capabilities to fend off market competition while drastically improving treatment prospects for patients suffering from complex diseases like multiple sclerosis.
The patent not only covers the drug itself but extends to various forms, including salts and solvates, used in all dosing regimens as indicated on the label. This comprehensive coverage ensures that even alternative formulations would be protected under the patent, positioning Immunic advantageously within the marketplace. Daniel Vitt, Immunic's Chief Executive Officer, articulated the importance of this development, indicating that it significantly bolsters the company's competitive edge against other forms of treatment for diseases, including multiple sclerosis (MS).
What’s more, the recent patent aligns with Immunic's multipronged intellectual property strategy, which includes a robust portfolio of additional patents. These cover aspects such as the drug's composition of matter, treatment protocols for multiple sclerosis, and various dosing methodologies derived from clinical trials. With these patents set to protect their innovations until at least 2041 in the U.S. and 2039 in Europe, Immunic positions itself for long-term success in a rapidly evolving industry.
Vidofludimus calcium employs a unique mechanism that integrates neuroprotective, anti-inflammatory, and anti-viral properties targeting the intricate pathology of multiple sclerosis. By selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH), it has demonstrated the ability to activate the nuclear receptor-related 1 (Nurr1), a transcription factor linked to neuroprotection. Currently, vidofludimus is undergoing late-stage clinical trials for treating relapsing MS, with phase 2 results indicating promising efficacy in reducing brain lesions and alleviating disability progression. The positive outcomes observed in clinical settings underscore the drug's potential, with over 3,400 participants already exposed to the treatment, asserting its acceptable safety and tolerability profile.
In addition to ms, future applications for vidofludimus calcium might address other neurodegenerative diseases, based on ongoing patent applications. These seek to expand the application of the drug to other forms and indicates a strategic foresight by Immunic to leverage their IP portfolio effectively. As they continue to pursue regulatory approval, Immunic remains committed to reinforcing its market position, primarily through the development of vidofludimus calcium and its associated conditions.
Immunic's reach isn't confined to just the European market; their patent strategy is global, adhering to various jurisdictions and reinforcing their stance in a competitive landscape. As they continue to innovate and evolve their product line, Immunic is poised to make a significant impact in treating chronic inflammatory and autoimmune diseases worldwide.
In summary, the securing of this European patent is not merely a legal victory but a critical step in solidifying Immunic’s status as a leader in biotechnology, amplifying its capabilities to fend off market competition while drastically improving treatment prospects for patients suffering from complex diseases like multiple sclerosis.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.